The global RNA analysis market is projected to reach USD 8.7 billion by 2025, at a CAGR of 13.9%. The growth of this market is majorly driven by the increasing demand for personalized medicine, increasing pharmaceutical and biotechnology R&D expenditure and government funding for omics, and the increasing applications of RNA sequencing in the transcriptomics market. 

Personalized medicine, which has become a core area of research in the healthcare industry, has entered mainstream clinical practice and is changing how many diseases are identified, classified, and treated. These advancements are particularly evident in the area of oncology. 

According to the Personalized Medicine Coalition report (2017), the number of personalized drugs, treatments, and diagnostic products has increased since 2006, and this trend is expected to continue in the coming years.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=240344576 

With the widespread implementation of novel applications, the use of transcriptomics research extends all the way from the discovery of novel drugs, vaccines, and diagnostic targets, toxicology, and identification of surrogate markers of activity in clinical research to the ability to provide information on the mechanisms of drug action. This requires the use of different types of platforms and instruments as well as laboratory documentation systems, contributing to the high cost of analytics.

Toxicogenomics is expected to grow at the highest rate during the forecast period

Based on application, the RNA analysis/transcriptomics market is segmented into clinical diagnostics, drug discovery, toxicogenomics, and comparative transcriptomics. The toxicogenomics application segment is expected to grow at the highest CAGR during the forecast period, primarily due to the increasing research focus on ADE studies and the technological advancements are taking place in the field of omics.

The pharmaceutical & biotechnology end-user segment is expected to account for the largest share of the RNA analysis/transcriptomics market

The RNA analysis/transcriptomics market, by end-user, is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & diagnostic centers, and contract research organizations. The pharmaceutical & biotechnology companies segment accounted for the largest market share in 2019. The large share of this segment can be attributed to the increased funding and government support for personalized drug discovery, growing use of omics-technologies, and the increasing use of RNA-seq methods for the discovery of disease as well as therapeutic targets.

Asia Pacific is expected to account for the highest CAGR for players operating in the RNA analysis/transcriptomics market

The Asia Pacific RNA analysis/transcriptomics market is expected to grow at the highest CAGR from 2020 to 2025. The increasing investments by governments and industries, growing biotechnology research in APAC countries, and the rising awareness about personalized therapeutics are expected to drive the growth of this regional market during the forecast period. Furthermore, the increasing focus on Asia Pacific countries due to their low-cost manufacturing advantage is expected to provide growth opportunities for manufacturers.

The prominent players in this market are Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US).